Eagle's Eye View: Lifestyle Intervention Benefits Health Status in ANOCA Patients
In this week’s View, Dr. Eagle looks at the wide variation in antithrombotic regimens after valve-in-valve transcatheter aortic valve replacement (TAVR). Next, he examines PARTNER-3, a 7-year study on TAVR versus surgical aortic valve replacement (SAVR) outcomes in low-risk patients. He then offers a perspective on the effect of sex difference and delayed diagnosis in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) from amyloidosis. Finally, Dr. Eagle explores the prospective SAMCRO trial which evaluates lifestyle intervention in addition to medical therapy in patients with invasively confirmed angina with no obstructive coronary artery disease (ANOCA).
X Links:
- Kim Eagle, MD, MACC keaglemd
Clinical Topics: Anticoagulation Management, Cardiac Surgery, Cardiovascular Care Team, Diabetes and Cardiometabolic Disease, Heart Failure and Cardiomyopathies, Invasive Cardiovascular Angiography and Intervention, Prevention, Cardiac Surgery and Heart Failure, Acute Heart Failure, Diet
Keywords: EaglesEyeView, National Cardiovascular Data Registries, STS/ACC TVT Registry, Platelet Aggregation Inhibitors, Transcatheter Aortic Valve Replacement, Patient Reported Outcome Measures, Diet, Mediterranean, Anticoagulants, Heart Disease Risk Factors, Fibrinolytic Agents, Health Status, Delayed Diagnosis, Heart Failure, Cardiomyopathies, Risk Factors, Interventional Cardiology, Registries
